The case of an elderly woman is reported in whom alendronate, given for osteoporosis, led to severe hypocalcaemia a few days after starting the drug treatment. This was caused by the unmasking of previously unrecognised hypoparathyroidism. (Postgrad Med J 2000;76:417-419) 
Clinically she had positive Schultze, Chvostek, and Trousseau signs. Her serum ionised calcium concentration was 0.8 mmol/l (normal 1.1-1.4) and inorganic serum phosphorus 2.0 mmol/l (normal 1.0-1.4); results of thyroid function tests were normal. An electrocardiogram revealed a QTc interval of 0.54 seconds. Her serum intact parathyroid hormone concentration was 14 pg/ml (normal 10-65); this was inappropriately low for her serum calcium concentrations. The patient was managed with intravenous calcium chloride infusion for hypocalcaemia. Alendronate was discontinued. Clinical symptoms and signs of hypocalcaemia and cardiac failure resolved when serum calcium concentrations reached 1.0 mmol/l. She was discharged on calcium carbonate 3 g/day and calcitriol 0.75 µg/day.
Box 1: Learning point
Alendronate (and other bisphosphonates) may lead to symptomatic hypocalcaemia in patients with pre-existing subclinical hypoparathyroidism.
Box 2: Drugs causing hypocalcaemia
Complexing anions x Phosphate: oral, rectal, intravenous In this patient the most likely explanation of hypocalcaemia is the unmasking of pre-existing subclinical hypocalcaemia caused by hypoparathyroidism, by alendronate therapy. The duration of hypoparathyroidism is diYcult to date in this patient.
Alendronate therapy leads to short term transient asymptomatic reductions in serum calcium concentrations, which is restored towards normal by parathyroid hormone release.
5 Patients who are unable to mount a compensatory response because of pre-existing parathyroid dysfunction may present with symptomatic hypocalcaemia. Other bisphosphonates are also likely to produce similar complication since the underlying mechanism of action is the same. Extensive literature search revealed only one other subsequent report of a similar patient.
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Follow up
There has been no recurrence of hypocalcaemia over a follow up period of four months. The patient continues to be on regular L-thyroxine, calcium carbonate, and calcitriol.
A learning point and a list of drugs causing hypocalcaemia are shown in boxes 1 and 2. 
Commentary-bisphosphonates and calcium homoeostasis M Pirmohamed
Bisphosphonates are synthetic analogues of pyrophosphate (antiscaling agents), and are mainly used in the treatment of hypercalcaemia, Paget's disease of bone, and osteoporosis. The latter is by far their most important indication with latest figures indicating that one in three women and one in 12 men over the age of 50 years will have an osteoporotic fracture.
1
Bisphosphonates decrease bone resorption by inhibiting osteoclastic activity. This is accompanied by an increase in calcium balance and in the mineral content of bone. The consequent increase in bone mass is the basis by which these compounds prevent osteoporosis in man. In hypercalcaemia of malignancy, their ability to inhibit bone resorption makes them most eVective when osteolytic, rather than humoral, mechanisms are involved.
2 Indeed, normalisation of the calcium concentrations is often followed by transient hypocalcaemia; however, this is rarely clinically significant.
What eVect do bisphosphonates have on serum calcium concentrations in normocalcaemic conditions such as osteoporosis and Paget's disease? In the case described by Kashyap and Kashyap, a 68 year old woman with osteoporosis developed clinically symptomatic hypocalcaemia after taking alendronate (5 mg/day) for 10 days. Intuitively, given the mode of action of bisphosphonates, this would not be considered to be an unexpected observation. Indeed, the serum calcium concentration is well known to decrease on initiating therapy with bisphosphonates, particularly when they are used intravenously. However, this is short lasting and usually clinically asymptomatic. It is rapidly followed by restoration of serum calcium to normal. 3 The mechanism by which this occurs is through a negative feed-back loop which increases parathyroid hormone (PTH) secretion within minutes. PTH in turn increases serum calcium concentrations by increasing bone resorption, intestinal calcium absorption, and renal tubular reabsorption of calcium. It is important to note that the parathyroid response to a hypocalcaemic challenge is not aVected by long term bisphosphonate therapy. 4 This is a reassuring observation given that in conditions such as osteoporosis, these drugs will have to be used for many years. Thus, clinically significant hypocalcaemia is only likely to occur in patients with deficient parathyroid hormone secretion, as observed in the patient reported in this issue and in other recent case reports with alendronate 5 and pamidronate. In summary, although bisphosphonates lead to a decrease in serum calcium, in most patients rapidly acting homoeostatic mechanisms involving an increase in PTH secretion lead to a restoration in calcium concentrations. In patients with known or suspected hypoparathyroidism, for example after thyroid or parathyroid surgery, these compensatory mechanisms will be absent, and bisphosphonate therapy can lead to symptomatic hypocalcaemia. In such patients, alternative therapies should be considered together with calcium and vitamin D supplementation. Incidentally, a small area of uptake was seen superior to the eutopic thyroid which corresponded to the area at the posterior aspect of the tongue and was consistent with the presence of lingual thyroid (see figs 1A and B). There was no salivary gland uptake. The patient underwent successful iodine-131 ablation therapy.
Ectopic thyroid tissue results due to abnormal migration of the thyroid gland from the base of the tongue to its normal pre-tracheal position. The prevalence of ectopic thyroid tissue is between 7%-10% with lingual thyroid accounting for 90% of such cases. Mutations in thyroid transcription factors 1 and 2 have been found in patients with thyroid agenesis and ectopic thyroid tissue. Lingual thyroid lies on the posterior aspect of the tongue and oral examination is usually normal. Invasive fibre optic laryngoscopy is generally needed to visualise the ectopic tissue in such location. Our patient refused any invasive procedure. 
